These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 30139491)

  • 1. Improving the Use of Primary Prevention Implantable Cardioverter-Defibrillators Therapy With Validated Patient-Centric Risk Estimates.
    Levy WC; Hellkamp AS; Mark DB; Poole JE; Shadman R; Dardas TF; Anderson J; Johnson G; Fishbein DP; Lee KL; Linker DT; Bardy GH
    JACC Clin Electrophysiol; 2018 Aug; 4(8):1089-1102. PubMed ID: 30139491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators.
    Bilchick KC; Wang Y; Cheng A; Curtis JP; Dharmarajan K; Stukenborg GJ; Shadman R; Anand I; Lund LH; Dahlström U; Sartipy U; Maggioni A; Swedberg K; O'Conner C; Levy WC
    J Am Coll Cardiol; 2017 May; 69(21):2606-2618. PubMed ID: 28545633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does the Implantable Cardioverter-Defibrillator Benefit Vary With the Estimated Proportional Risk of Sudden Death in Heart Failure Patients?
    Levy WC; Li Y; Reed SD; Zile MR; Shadman R; Dardas T; Whellan DJ; Schulman KA; Ellis SJ; Neilson M; O'Connor CM;
    JACC Clin Electrophysiol; 2017 Mar; 3(3):291-298. PubMed ID: 28553663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of sudden cardiac death in Japanese heart failure patients: international validation of the Seattle Proportional Risk Model.
    Fukuoka R; Kohno T; Kohsaka S; Shiraishi Y; Sawano M; Abe T; Nagatomo Y; Goda A; Mizuno A; Fukuda K; Shadman R; Dardas TF; Levy WC; Yoshikawa T
    Europace; 2020 Apr; 22(4):588-597. PubMed ID: 32155253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk Models for Prediction of Implantable Cardioverter-Defibrillator Benefit: Insights From the DANISH Trial.
    Kristensen SL; Levy WC; Shadman R; Nielsen JC; Haarbo J; Videbæk L; Bruun NE; Eiskjær H; Wiggers H; Brandes A; Thøgersen AM; Hassager C; Svendsen JH; Høfsten DE; Torp-Pedersen C; Pehrson S; Signorovitch J; Køber L; Thune JJ
    JACC Heart Fail; 2019 Aug; 7(8):717-724. PubMed ID: 31302052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seattle proportional risk model in GISSI-HF: Estimated benefit of ICD in patients with EF less than 50.
    Bockus LB; Shadman R; Poole JE; Dardas TF; Lucci D; Meessen J; Latini R; Maggioni A; Levy WC
    Am Heart J; 2024 Sep; 275():35-44. PubMed ID: 38825218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel method to predict the proportional risk of sudden cardiac death in heart failure: Derivation of the Seattle Proportional Risk Model.
    Shadman R; Poole JE; Dardas TF; Mozaffarian D; Cleland JG; Swedberg K; Maggioni AP; Anand IS; Carson PE; Miller AB; Levy WC
    Heart Rhythm; 2015 Oct; 12(10):2069-77. PubMed ID: 26142301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling defibrillation benefit for survival among cardiac resynchronization therapy defibrillator recipients.
    Bilchick KC; Wang Y; Curtis JP; Cheng A; Dharmarajan K; Shadman R; Dardas TF; Anand I; Lund LH; Dahlström U; Sartipy U; Maggioni A; O'Connor C; Levy WC
    Am Heart J; 2020 Apr; 222():93-104. PubMed ID: 32032927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein biomarkers identify patients unlikely to benefit from primary prevention implantable cardioverter defibrillators: findings from the Prospective Observational Study of Implantable Cardioverter Defibrillators (PROSE-ICD).
    Cheng A; Zhang Y; Blasco-Colmenares E; Dalal D; Butcher B; Norgard S; Eldadah Z; Ellenbogen KA; Dickfeld T; Spragg DD; Marine JE; Guallar E; Tomaselli GF
    Circ Arrhythm Electrophysiol; 2014 Dec; 7(6):1084-91. PubMed ID: 25273351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Implantable Cardioverter Defibrillators With Survival in Patients With and Without Improved Ejection Fraction: Secondary Analysis of the Sudden Cardiac Death in Heart Failure Trial.
    Adabag S; Patton KK; Buxton AE; Rector TS; Ensrud KE; Vakil K; Levy WC; Poole JE
    JAMA Cardiol; 2017 Jul; 2(7):767-774. PubMed ID: 28724134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SCD-HeFT: Use of R-R interval statistics for long-term risk stratification for arrhythmic sudden cardiac death.
    Au-Yeung WT; Reinhall PG; Poole JE; Anderson J; Johnson G; Fletcher RD; Moore HJ; Mark DB; Lee KL; Bardy GH
    Heart Rhythm; 2015 Oct; 12(10):2058-66. PubMed ID: 26096609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure.
    Elming MB; Nielsen JC; Haarbo J; Videbæk L; Korup E; Signorovitch J; Olesen LL; Hildebrandt P; Steffensen FH; Bruun NE; Eiskjær H; Brandes A; Thøgersen AM; Gustafsson F; Egstrup K; Videbæk R; Hassager C; Svendsen JH; Høfsten DE; Torp-Pedersen C; Pehrson S; Køber L; Thune JJ
    Circulation; 2017 Nov; 136(19):1772-1780. PubMed ID: 28877914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population.
    Levy WC; Lee KL; Hellkamp AS; Poole JE; Mozaffarian D; Linker DT; Maggioni AP; Anand I; Poole-Wilson PA; Fishbein DP; Johnson G; Anderson J; Mark DB; Bardy GH
    Circulation; 2009 Sep; 120(10):835-42. PubMed ID: 19704100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes After Implantable Cardioverter-Defibrillator Generator Replacement for Primary Prevention of Sudden Cardiac Death.
    Madhavan M; Waks JW; Friedman PA; Kramer DB; Buxton AE; Noseworthy PA; Mehta RA; Hodge DO; Higgins AY; Webster TL; Witt CM; Cha YM; Gersh BJ
    Circ Arrhythm Electrophysiol; 2016 Mar; 9(3):e003283. PubMed ID: 26921377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic implantable cardioverter defibrillator treatment in patients with end-stage heart failure awaiting heart transplantation.
    Fröhlich GM; Holzmeister J; Hübler M; Hübler S; Wolfrum M; Enseleit F; Seifert B; Hürlimann D; Lehmkuhl HB; Noll G; Steffel J; Falk V; Lüscher TF; Hetzer R; Ruschitzka F
    Heart; 2013 Aug; 99(16):1158-65. PubMed ID: 23813845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trials.
    Friedman DJ; Al-Khatib SM; Zeitler EP; Han J; Bardy GH; Poole JE; Bigger JT; Buxton AE; Moss AJ; Lee KL; Steinman R; Dorian P; Cappato R; Kadish AH; Kudenchuk PJ; Mark DB; Inoue LYT; Sanders GD
    Am Heart J; 2017 Sep; 191():21-29. PubMed ID: 28888266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of primary prevention implantable cardioverter-defibrillator use in heart failure with reduced ejection fraction: impact of the predicted risk of sudden cardiac death and all-cause mortality.
    Schrage B; Lund LH; Benson L; Dahlström U; Shadman R; Linde C; Braunschweig F; Levy WC; Savarese G
    Eur J Heart Fail; 2022 Jul; 24(7):1212-1222. PubMed ID: 35502681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial.
    Packer DL; Prutkin JM; Hellkamp AS; Mitchell LB; Bernstein RC; Wood F; Boehmer JP; Carlson MD; Frantz RP; McNulty SE; Rogers JG; Anderson J; Johnson GW; Walsh MN; Poole JE; Mark DB; Lee KL; Bardy GH
    Circulation; 2009 Dec; 120(22):2170-6. PubMed ID: 19917887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of the 6-min walk distance to identify variations in treatment benefits from implantable cardioverter-defibrillator and amiodarone: results from the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial).
    Fishbein DP; Hellkamp AS; Mark DB; Walsh MN; Poole JE; Anderson J; Johnson G; Lee KL; Bardy GH;
    J Am Coll Cardiol; 2014 Jun; 63(23):2560-2568. PubMed ID: 24727258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving sudden cardiac death risk stratification by evaluating electrocardiographic measures of global electrical heterogeneity and clinical outcomes among patients with implantable cardioverter-defibrillators: rationale and design for a retrospective, multicenter, cohort study.
    Waks JW; Hamilton C; Das S; Ehdaie A; Minnier J; Narayan S; Niebauer M; Raitt M; Tompkins C; Varma N; Chugh S; Tereshchenko LG
    J Interv Card Electrophysiol; 2018 Jun; 52(1):77-89. PubMed ID: 29541969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.